701
Participants
Start Date
August 18, 2020
Primary Completion Date
March 30, 2022
Study Completion Date
March 30, 2022
Fenofibrate/fenofibric acid
The randomized intervention will be fenofibrate (Tricor) at a dose of 145 mg/d or dose-equivalent preparation of fenofibrate or fenofibric acid, for 10 days. In all cases, appropriate dose reductions will be implemented for patients with chronic kidney disease as per the approved preparation label. The intended duration of randomized treatment will be for 10 days.
Placebo
The control intervention will be a placebo, for 10 days.
Usual care
All participants will otherwise receive usual medical care
University of Pennsylvania Health System, Philadelphia
Collaborators (1)
University of Arizona
OTHER
Universidad Católica de Santa María
OTHER
Hospital Nacional Adolfo Guevara Velasco
OTHER
Hospital Nacional Edgardo Rebagliati Martins
OTHER
Hospital Nacional Alberto Sabogal Sologuren
OTHER
Hospital Nacional Guillermo Almenara Irigoyen
OTHER
Hospital Nacional Carlos Alberto Seguin Escobedo - EsSalud
OTHER
Universidad de Santander
OTHER
National Center for Advancing Translational Sciences (NCATS)
NIH
Hospital Civil de Guadalajara
OTHER
Hospital Nacional Dos De Mayo
OTHER
Hospital Central Fuerza Aérea del Perú
OTHER
Hospital Militar Central.Coronel Luis Arias Schereiber
OTHER
Hospital Victor Lazarte Echegaray
OTHER
University Hospital, Ioannina
OTHER
AHEPA University Hospital
OTHER
Sotiria Thoracic Diseases Hospital of Athens
OTHER
Thriasio General Hospital of Elefsina
OTHER
University Hospital, Alexandroupolis
OTHER
G.Gennimatas General Hospital
OTHER
Biomelab S.A.S.
INDUSTRY
Fundación Oftalmológica de Santander. Santander, Colombia
OTHER
IPS Centro Científico Asistencial. Barranquilla, Colombia
OTHER
Fundación Cardiomet. Quindio, Colombia
OTHER
ClÍnica de Marly
OTHER
Clínica Internacional
OTHER
University of Pennsylvania
OTHER